Incyte

Incyte Days Sales Outstanding

The Days Sales Outstanding (DSO) of Incyte (INCY) as of Nov 4, 2026 is 72.73. In the previous year, Days Sales Outstanding (DSO) was 73.42 — a change of -0.95% (lower).

Days Sales Outstanding

72.73

YoY

-0.95%

Last updated:

Days Sales Outstanding (DSO) of Incyte is 2025 72.73 . Days Sales Outstanding (DSO) of Incyte was 2024 73.42 . It decreases by -0.95% lower compared to the previous year.

The Incyte Days Sales Outstanding history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

Days Sales Outstanding
Date
Days Sales Outstanding
Jan 1, 2018
59.52 USD
Jan 1, 2019
52.14 USD
Jan 1, 2020
65.95 USD
Jan 1, 2021
75.33 USD
Jan 1, 2022
69.34 USD
Jan 1, 2023
73.44 USD
Jan 1, 2024
73.42 USD
Jan 1, 2025
72.73 USD
The Incyte Days Sales Outstanding history
YEARDays Sales OutstandingYoY
72.73-0.95%
73.42-0.02%
73.44+5.91%
69.34-7.95%
75.33+14.23%
65.95+26.47%
52.14-12.40%
59.52-5.35%
62.89+28.04%
49.12-11.41%
55.45+34.20%
41.32—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Incyte Stock analysis

What does Incyte do? The Incyte Corporation is a global biotechnology company specializing in the research and development of drugs for the treatment of cancer and other serious diseases. Incyte was founded in 1991 in Delaware, USA, by Roy Whitfield, a biotech entrepreneur, with the aim of finding new approaches to drug discovery. The company initially focused on developing DNA sequencing technologies and building an extensive database for drug identification. Over the years, Incyte expanded its expertise in genomics research and collaborated with pharmaceutical companies to develop new medications. In 2002, Incyte entered into a strategic alliance with Eli Lilly and Company to jointly research drugs for cancer and other diseases. Today, Incyte offers a wide range of medications for the treatment of cancer, immune and inflammatory disorders, and rare genetic diseases. The company's business model is based on the discovery and development of new drugs, utilizing its strengths in genomics research and biomarker development to identify and develop targeted therapies. Incyte has also increasingly focused on the development of immunotherapies, particularly antibodies targeting cancer and other diseases by activating the immune system. The company has positioned itself as a leading provider of genetic tests for rare diseases in the United States, offering a broad range of diagnostic tests based on genetic mutations. Incyte is a rapidly growing company with a strong emphasis on innovation and research. It has a strong presence in the field of cancer therapy and is working to expand its expertise in immunology and genomics research. Incyte is considered a promising candidate for future growth and success in drug development in the biotech industry. Incyte is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Incyte stock

Days Sales Outstanding (DSO) of Incyte is 72.73 in 2025.

Days Sales Outstanding (DSO) of Incyte changed from 73.42 to 72.73, representing a -0.95% change. The value is lower than the previous year.

On Eulerpool you can find the complete historical development of Days Sales Outstanding (DSO) Incyte since 2006 – with annual values, charts, and detailed analysis.

DSO measures the average number of days it takes to collect payment after a sale. Lower DSO indicates faster cash collection.

A 'good' varies by industry and company stage. On Eulerpool, you can compare Days Sales Outstanding (DSO)'s Incyte with sector peers and the industry average to assess whether it is attractive.

To evaluate Days Sales Outstanding (DSO)'s, it is essential to compare it with peers in the same industry and sector. On Eulerpool, you can find direct industry comparisons for Days Sales Outstanding (DSO).

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Profitability — Incyte

All Key Metrics — Incyte